Diverticulitis: Clinical Trials

3 trials for Diverticulitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 terminated. 3 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 33Terminated 3
Phase 21Terminated 1

Follow Diverticulitis: new trials by email Literature Review of Diverticulitis trials Research Report on Diverticulitis

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications.
Rifaximin delayed released 400mg Tablet, Placebo - Diverticulitis
Phase 2 / Phase 3TerminatedAlfasigma S.p.A.1932018-07-022021-10-20
Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis
Mesalazine, Placebo - Diverticulitis
Phase 3TerminatedDr. Falk Pharma GmbH3302010-01-012017-07-21
Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis
Mesalazine, Placebo - Diverticulitis
Phase 3TerminatedDr. Falk Pharma GmbH3452008-01-012017-07-24

Broader conditions

Digestive System Diseases (3)  ·  Diverticular Diseases (3)  ·  Gastroenteritis (3)  ·  Gastrointestinal Diseases (3)

Interventions

Mesalamine (2)  ·  Tablets (1)

Sponsors

Dr. Falk Pharma GmbH (2)  ·  Alfasigma S.p.A. (1)

Countries

Germany (2)  ·  France (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Spain (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Wolfgang Kruis, Professor (2)

Results publications

PMID 28543263, PMID 28707787, PMID 28707796

NIH funding

2009 (1), 2017 (1)